Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan
Authors
Keywords
-
Journal
Liver Cancer
Volume -, Issue -, Pages 1-13
Publisher
S. Karger AG
Online
2023-10-12
DOI
10.1159/000534304
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcome of patients with hepatocellular carcinoma and liver dysfunction under Immunotherapy: a systematic review and meta-analysis
- (2023) Ismael El Hajra et al. HEPATOLOGY
- Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
- (2023) Masatoshi Kudo Liver Cancer
- AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
- (2023) Amit G. Singal et al. HEPATOLOGY
- Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
- (2023) Kiyoshi Hasegawa et al. HEPATOLOGY RESEARCH
- Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study
- (2023) Masatoshi Kudo et al. Liver Cancer
- The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
- (2023) Masatoshi Kudo Hepatobiliary Surgery and Nutrition
- Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials
- (2023) Claudia Angela Maria Fulgenzi et al. JHEP Reports
- Breakthroughs in Hepatocellular Carcinoma Therapies
- (2023) Amit G. Singal et al. Clinical Gastroenterology and Hepatology
- A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
- (2023) Masatoshi Kudo et al. Liver Cancer
- Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
- (2023) Ciro Celsa et al. Liver Cancer
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
- (2022) Masatoshi Kudo et al. Liver Cancer
- Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
- (2022) Masatoshi Kudo Liver Cancer
- Objective response by mRECIST to initial lenvatinib therapy is an independent factor contributing to deep response in hepatocellular carcinoma treated with lenvatinib-transcatheter arterial chemoembolization sequential therapy
- (2022) Hidekatsu Kuroda et al. Liver Cancer
- New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
- (2022) Masatoshi Kudo International Journal of Clinical Oncology
- Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based Combinations
- (2022) Anthony C. Bejjani et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment
- (2022) Kazuomi Ueshima et al. Liver Cancer
- A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival.
- (2022) Tatsuya Yamashita et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
- (2022) Zhenwei Peng et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-unsuitable Intermediate-stage Hepatocellular Carcinoma
- (2022) Masatoshi Kudo Liver Cancer
- Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study
- (2022) Masatoshi Kudo et al. JOURNAL OF HEPATOLOGY
- Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and TACE to Achieve Synergistic Effects
- (2022) Masatoshi Kudo Liver Cancer
- Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma
- (2022) Bo Zhang et al. European Journal of Internal Medicine
- IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study
- (2022) Masatoshi Kudo et al. Liver Cancer
- Report of the 21st Nationwide Follow‐Up Survey of Primary Liver Cancer in Japan (2010–2011)
- (2021) Masatoshi Kudo et al. HEPATOLOGY RESEARCH
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- (2021) A. Vogel et al. ANNALS OF ONCOLOGY
- Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
- (2021) Zhigang Fu et al. Hepatology International
- Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
- (2021) Masatoshi Kudo et al. Liver Cancer
- Report of the 22nd Nationwide Follow‐Up Survey of Primary Liver Cancer in Japan (2012–2013)
- (2021) Masatoshi Kudo et al. HEPATOLOGY RESEARCH
- CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
- (2021) Masatoshi Kudo et al. JOURNAL OF HEPATOLOGY
- Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
- (2021) Masatoshi Kudo Liver Cancer
- Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies
- (2021) Masatoshi Kudo et al. CLINICAL CANCER RESEARCH
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
- (2021) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Immunotherapies for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials
- (2021) Giuseppe Cabibbo et al. Liver Cancer
- Surgery Versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: a Randomized Controlled Trial (SURF-Trial)
- (2021) Tadatoshi Takayama et al. Liver Cancer
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
- (2021) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
- (2020) Josep M. Llovet et al. HEPATOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
- (2020) Masatoshi Kudo et al. Liver Cancer
- Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- (2020) Kazuomi Ueshima et al. Liver Cancer
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial).
- (2019) Namiki Izumi et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
- (2019) MinKe He et al. JAMA Oncology
- Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
- (2019) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
- (2019) Tatsuya Yamashita et al. JOURNAL OF GASTROENTEROLOGY
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
- (2018) Sheng-Nan Lu et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
- (2018) Ryosuke Tateishi et al. JOURNAL OF GASTROENTEROLOGY
- Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study
- (2018) Tsuyoshi Shimamura et al. TRANSPLANT INTERNATIONAL
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
- (2015) Takeshi Terashima et al. HEPATOLOGY RESEARCH
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
- (2014) Masatoshi Kudo et al. HEPATOLOGY
- Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
- (2014) Masatoshi Kudo et al. ONCOLOGY
- Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization
- (2014) Sadahisa Ogasawara et al. ONCOLOGY
- Validation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSGJ
- (2014) Tadaaki Arizumi et al. ONCOLOGY
- How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective
- (2014) Jean-Luc Raoul et al. Liver Cancer
- Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel
- (2013) Ann Lii Cheng et al. LIVER INTERNATIONAL
- A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma
- (2012) Kai Feng et al. JOURNAL OF HEPATOLOGY
- Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey
- (2012) Kiyoshi Hasegawa et al. JOURNAL OF HEPATOLOGY
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
- (2011) Masatoshi Kudo et al. DIGESTIVE DISEASES
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria
- (2010) Jiwei Huang et al. ANNALS OF SURGERY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started